You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 19, 2024

Claims for Patent: 4,409,212

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 4,409,212

Title:	Method of preventing and treating cerebral insufficiency
Abstract:	The invention relates to a method of preventing or treating cerebral insufficiency, which method comprises administering to a human being in need of such treatment, orally or rectally, a prophylactic or a therapeutically effective amount of a compound of the general formula I ##STR1## wherein X.sub.1 is hydrogen, halogen having an atomic number up to 35, or is cyano, and X.sub.2 and Y together are an additional bond, or X.sub.1 and X.sub.2 together are the oxo radical and Y is hydrogen, or X.sub.1 is hydroxy and X.sub.2 and Y are hydrogen. Examples of suitable compounds are 10,11-dihyro-10-hydroxy-5H-dibenz[b,f]azepine-5-carboxamide, 10,11-dihydro-10-oxo-5H-dibenz[b,f]azepine-5-carboxamide and, in particular, carbamazepine (5H-dibenz[b,f]azepine-5-carboxamide).
Inventor(s):	Mondadori; Cesare (Don Mills, CA)
Assignee:	Ciba-Geigy Corporation (Ardsley, NY)
Application Number:	06/366,792
Patent Claims:	1. A method of preventing or treating imparied memory conditions comprising administering to a human being in need of such treatment, orally or rectally, a prophylactic or a therapeutically effective amount of a compound of the general formula ##STR3## wherein X.sub.1 is hydrogen, halogen having an atomic number up to 35, or is cyano, and X.sub.2 and Y together are an additional bond, or X.sub.1 and X.sub.2 together are the oxo radical and Y is hydrogen, or X.sub.1 is hydroxy and X.sub.2 and Y are hydrogen. 2. The method according to claim 1 wherein the impaired memory conditions comprise senile dementia, multi-infarction dementia, or Alzheimer's dementia. 3. A method according to claim 1, which comprises administration of a compound of the general formula I, wherein X.sub.1 is hydrogen, chlorine or cyano, and X.sub.2 and Y together are an additional bond, or X.sub.1 and X.sub.2 together are the oxo radical and Y is hydrogen, or X.sub.1 is hydroxy and X.sub.2 and Y are hydrogen. 4. A method according to claim 1, which comprises administration of 5H-dibenz[b,f]azepine-5-carboxamide. 5. A method according to claim 1, which comprises administration of 10,11-dihydro-10-oxo-5H-dibenz[b,f]-azepine-5-carboxamide. 6. A method according to claim 1, which comprises administration of 10,11-dihydro-10-hydroxy-5H-dibenz[b,f]-azepine-5-carboxamide. 7. A method according to claim 1, which comprises administration of a compound of the general formula I in an amount from 2 to 17 mg/kg per day. 8. A method according to claim 18, which comprises administration of a compound of the general formula I to an adult person of normal weight in an amount from about 150 to 1200 mg per day.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.